Mosaic ImmunoEngineering Inc. reported significant financial challenges in its latest 10-K filing for the fiscal year ending December 31, 2025. The company recorded a net loss of approximately $687,846, a decrease from the previous year's loss of $921,983. As of the end of 2025, Mosaic had cash and cash equivalents of just $3,622, with current liabilities amounting to $6,030,055, raising substantial doubt about its ability to continue operations without securing additional funding. The company has incurred operating losses since its inception, accumulating a deficit of $9,526,166.
In terms of operational developments, Mosaic has been actively pursuing strategic partnerships to enhance its product pipeline. Notably, on April 26, 2024, the company entered into a binding term sheet with Oncotelic Therapeutics, Inc. to acquire rights to certain cancer therapies and AI technologies. This agreement, valued at $15 million in common stock, is contingent upon various conditions, including shareholder approval and waivers from holders of convertible notes. However, the binding term sheet is set to expire on June 30, 2025, and ongoing discussions may not lead to a definitive agreement.
Mosaic's workforce remains minimal, with only two full-time and five part-time employees as of December 31, 2025. The company has historically relied on consultants for expertise in product development and regulatory strategy. The limited employee count reflects the company's constrained financial resources, which have necessitated scaling back operations and development activities. The filing indicates that the company has not advanced any product candidates to clinical development, and its research and development expenses were approximately $64,000 for the year, primarily related to personnel costs.
Looking ahead, Mosaic's management has acknowledged the need for substantial additional funding to support its operations and research initiatives. The company plans to finance its activities through potential equity and debt offerings, although it faces challenges in raising capital due to its limited technologies and current market conditions. The filing emphasizes that without securing sufficient capital, Mosaic may be forced to cease operations altogether, underscoring the precarious nature of its financial position and the urgent need for strategic partnerships or funding solutions to ensure its survival and growth in the competitive biotechnology landscape.
About Mosaic ImmunoEngineering Inc.
Mosaic ImmunoEngineering is a biotechnology company focused on developing immunotherapies for cancer treatment. It aims to identify, license, and acquire innovative product candidates and platforms, leveraging expertise in immuno-oncology. The company explores novel therapies, including AI-driven combination strategies, with a pipeline primarily in early-stage preclinical development, targeting unmet medical needs in oncology markets worldwide.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.